Singapore legislation
Regulation 35
of Health Products (Cell, Tissue and Gene Therapy Products) Regulations 2021
Regulation 35
Duty to maintain records of defects and adverse effects
Subregulation 1
Every manufacturer, importer or registrant of a CTGT product must —
maintain a record of every event or other occurrence that reveals any defect in the CTGT product or that concerns any adverse effect arising from the administration of the CTGT product; and
produce that record for inspection by the Authority or an enforcement officer as and when required by the Authority or enforcement officer.
Subregulation 2
A person mentioned in paragraph (1) must ensure that every record mentioned in that paragraph —
contains all the following information:
the proprietary name or appropriate non‑proprietary name of the CTGT product which is defective or of which an adverse effect has arisen from its administration;
the date on which the person first became aware of the event or occurrence;
the identification number or mark (including the control number, lot number, batch number or serial number) of the CTGT product;
the nature of the defect or adverse effect;
any other information that the Authority specifies in writing; and
is retained for at least 2 years after the expiry date of the CTGT product.
Subregulation 3
A person who fails to comply with paragraph (1) or (2) shall be guilty of an offence and shall be liable on conviction to a fine not exceeding $10,000 or to imprisonment for a term not exceeding 6 months or to both.
Subregulation 4
A person who, in compliance or purported compliance with paragraph (1) or (2), provides the Authority or an enforcement officer with any record which the person knows is false or misleading in a material particular shall be guilty of an offence and shall be liable on conviction to a fine not exceeding $20,000 or to imprisonment for a term not exceeding 12 months or to both.